Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update

Forte Biosciences, Inc. (NASDAQ:FBRX) was the target of a large growth in short interest in October. As of October 15th, there was short interest totalling 4,100 shares, a growth of 24.2% from the September 30th total of 3,300 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 9,600 shares, the days-to-cover ratio is presently 0.4 days.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital reissued a “buy” rating and issued a $3.00 price objective on shares of Forte Biosciences in a report on Monday, August 19th.

Forte Biosciences Stock Down 0.7 %

NASDAQ FBRX traded down $0.03 on Wednesday, reaching $4.55. 21,470 shares of the stock traded hands, compared to its average volume of 3,923. The company has a market cap of $6.64 million, a price-to-earnings ratio of -0.25 and a beta of 0.01. The firm’s fifty day simple moving average is $5.28 and its 200 day simple moving average is $1.87. Forte Biosciences has a 12 month low of $4.44 and a 12 month high of $21.25.

Forte Biosciences (NASDAQ:FBRX) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.11). As a group, equities research analysts forecast that Forte Biosciences will post -22.5 EPS for the current fiscal year.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.